2月龄婴儿出生前后暴露于选择性5-羟色胺再摄取抑制剂药物后的疼痛反应

合集下载
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

2月龄婴儿出生前后暴露于选择性5-羟色胺再摄取抑制剂药
物后的疼痛反应
Oberlander T.F.;Grunau R.E.;Fitzgerald C.;郭战宏
【期刊名称】《世界核心医学期刊文摘:儿科学分册》
【年(卷),期】2006(0)9
【摘要】Objective. In this prospective study,we examined biobehavioral responses to acute procedural pain at 2 months of age in infants with prenatal and postnatal selective serotonin reuptake inhibitor (SSRI) medication exposure. Based on previous findings showing reduced pain responses in newborns after prenatal exposure,we hypothesized that altered pain reactivity would also be found at 2 months of age. Methods. Facial action (Neonatal Facial Coding System) and cardiac autonomic reactivity derived from the respiratory activity and heart rate variability (HRV) responses to a painful event (heel-lance)were compared between 3 groups of infants:(1) infants with prenatal SSRI exposure alone (n=11; fluoxetine,n=2; paroxetine,n =9); (2) infants with prenatal and postnatal SSRI (via breast milk)-exposure (total n=30; fluoxetine,n=6; paroxetine,n=20; sertraline,n=4); and (3) control infants (n=22; nonexposed)-during baseline,lance,and recovery periods. Measures of maternal mood and drug levels were also obtained,and Bayley Scales of Infant Development-II were administered at ages 2 and 8 months. Results. Facial action increased in all groups immediately after the lance but was
significantly lower in the pSE group during the lance period. HR among infants in the pSE and ppSE groups was significantly lower during recovery. Using measures of HRV and the transfer relationship between heart rate and respiration,exposed infants had a greater return of parasympathetic cardiac modulation in the recovery period,whereas a sustained sympathetic response continued in control infants. Although postnatal exposure via breast milk was extremely low when infant drug levels could be detected in ppSE infants,changes in HR and HRV from lance to recovery were greater compared among infants with levels too low to be quantified. Neither maternal mood nor the presence of clonazepam influenced pain responses. Conclusions. Blunted facial-action responses were observed among infants with prenatal SSRI exposure alone,whereas both prenatal and postnatal exposure was associated with reduced parasympathetic withdrawal and increased parasympathetic cardiac modulation during recovery after an acute noxious event. These findings are consistent with patterns of pain reactivity observed in the newborn period in the same cohort. Given that postnatal exposure via breast milk was extremely low and altered biobehavioral pain reactivity was not associated with levels of maternal reports of depression,these data suggest possible sustained neurobehavioral outcomes beyond the newborn period. This is the first study of pain reactivity in infants with prenatal and postnatal SSRI exposure,and our findings were limited by the lack of a depressed nonmedicated control group,small sample size,and understanding of infant behaviors associated with pain reactivity that could have also have
been influenced by prenatal SSRI exposure. The developmental and clinical implications of our findings remain unclear,and the mechanisms that may have altered 5-hydroxytryptamine-mediated painmodulation in infants after SSRI exposure remain to be studied. Treating maternal depression with antidepressants during and after pregnancy and promoting breastfeeding in this setting should remain a key goal for all clinicians. Additional study is needed to understand the long-term effects of prenatal and early postnatal SSRI exposure.
【总页数】2页(P51-52)
【关键词】再摄取抑制剂;疼痛反应;出生前;色胺;SSRI;药物治疗;新生儿期;出生后;舍曲林;神经行为
【作者】Oberlander T.F.;Grunau R.E.;Fitzgerald C.;郭战宏
【作者单位】Biobehavioral Research Unit,Centre for Community Child Health Research,4480 Oak St,Vancouver,BC,Canada Dr.
【正文语种】中文
【中图分类】R725.9
【相关文献】
1.选择性5-羟色胺再摄取抑制剂类药物治疗脑卒中后抑郁的有效性和安全性研究[J], 李春燕
2.加拿大警示选择性5-羟色胺再摄取抑制剂和5-羟色胺-去甲肾上腺素再摄取抑制剂停药后发生性功能障碍的潜在风险 [J],
3.加拿大警示选择性5-羟色胺再摄取抑制剂和5-羟色胺-去甲肾上腺素再摄取抑制
剂停药后发生性功能障碍的潜在风险 [J],
4.加拿大警示选择性5-羟色胺再摄取抑制剂和5-羟色胺-去甲肾上腺素再摄取抑制剂停药后发生性功能障碍的潜在风险 [J],
5.孕期选择性5-羟色胺再摄取抑制剂暴露安全性的研究进展 [J], 张媛媛;李素仙;李志宏
因版权原因,仅展示原文概要,查看原文内容请购买。

相关文档
最新文档